ANI Pharma appoints Henry Gosebruch to board of directors

• ANI Pharmaceuticals appointed Henry Gosebruch to its board, effective Aug. 19, 2026.
• Gosebruch has been CEO of Lakefront Biotherapeutics NV since May 2025.
• He previously served as CEO of Neumora Therapeutics from July 2023 to February 2025.
• Earlier roles include AbbVie executive vice president and chief strategy officer from 2015 to 2023, leading corporate strategy and M&A.
• Director Muthusamy Shanmugam resigned from the board, effective immediately.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240655PRIMZONEFULLFEED9814675) on August 24, 2026, and is solely responsible for the information contained therein.